Needham Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $37

Benzinga Newsdesk www.benzinga.com Neutral 58.1%

Neg 0% Neu 58.1% Pos 0%

Needham analyst Ami Fadia initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $37.